Effect of Disease Pathologies on Transporter Expression and Function

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of clinical pharmacology

• Publication date

  2016-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/jcph.768PMID 27385176
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute kidney injury.

  2021cited by this paper
• Expression and regulation of ABC transporter genes during liver regeneration

  2018cited by this paper
• The transmembrane transporter ABCC3 participates in liver cancer progression and is a potential biomarker

  2016cited by this paper
• Quantitative targeted absolute proteomics of rat blood–cerebrospinal fluid barrier transporters: comparison with a human specimen

  2015cited by this paper
• Phytoestrogens Modulate Breast Cancer Resistance Protein Expression and Function at the Blood-Cerebrospinal Fluid Barrier.

  2015cited by this paper
• Mutations in SOD1 and FUS caused juvenile-onset sporadic amyotrophic lateral sclerosis with aggressive progression.

  2015cited by this paper
• The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).

  2015cited by this paper
• Differential Expression of Ion Channels and Transporters During Hepatocellular Carcinoma Development

  2015cited by this paper
• Expression of drug transporters in human kidney: impact of sex, age, and ethnicity

  2015cited by this paper
• Altered Renal Expression of Relevant Clinical Drug Transporters in Different Models of Acute Uremia in Rats. Role of Urea Levels

  2015cited by this paper
• [Drug-induced acute kidney injury].

  2015cited by this paper
• Apical ABC transporters and cancer chemotherapeutic drug disposition.

  2015cited by this paper
• Down-regulation of OATP1B proteins correlates with hyperbilirubinemia in advanced cholestasis.

  2015cited by this paper
• Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders.

  2015cited by this paper
• Solute Carrier Family of the Organic Anion-Transporting Polypeptides 1A2– Madin-Darby Canine Kidney II: A Promising In Vitro System to Understand the Role of Organic Anion-Transporting Polypeptide 1A2 in Blood-Brain Barrier Drug Penetration

  2015cited by this paper
• Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms.

  2015cited by this paper
• ABCB1 hypomethylation is associated with decreased antiplatelet effects of clopidogrel in Chinese ischemic stroke patients.

  2015cited by this paper
• OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma.

  2014cited by this paper
• A pilot study of leukocyte expression patterns for drug metabolizing enzyme and transporter transcripts in autoimmune glomerulonephritis

  2014cited by this paper
• OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma

  2014cited by this paper
• Modeling Human Nonalcoholic Steatohepatitis-Associated Changes in Drug Transporter Expression Using Experimental Rodent Models

  2014cited by this paper
• Experimental Nonalcoholic Steatohepatitis Increases Exposure to Simvastatin Hydroxy Acid by Decreasing Hepatic Organic Anion Transporting Polypeptide Expression

  2014cited by this paper
• Synergistic interaction between genetics and disease on pravastatin disposition.

  2014cited by this paper
• Effect of Lycopene Against Cisplatin-Induced Acute Renal Injury in Rats: Organic Anion and Cation Transporters Evaluation

  2014cited by this paper
• Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis

  2014cited by this paper
• Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis.

  2014cited by this paper
• Inhibiting drug efflux transporters improves efficacy of ALS therapeutics

  2014cited by this paper
• ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy

  2014cited by this paper
• Chronic Kidney Disease Results in Deficiency of ABCC6, the Novel Inhibitor of Vascular Calcification

  2014cited by this paper
• Hypoxia/Reoxygenation Stress Signals an Increase in Organic Anion Transporting polypeptide 1a4 (Oatp1a4) at the Blood–Brain Barrier: Relevance to CNS Drug Delivery

  2014cited by this paper
• Limited Sampling Model for Advanced Mycophenolic Acid Therapeutic Drug Monitoring After Liver Transplantation

  2014cited by this paper
• Running Title Page Running Title : Expression of drug uptake and efflux transporters in HCC

  2014cited by this paper
• Differential Expression of Drug Uptake and Efflux Transporters in Japanese Patients with Hepatocellular Carcinoma

  2014cited by this paper
• Modulation of P‐glycoprotein in rat brain microvessel endothelial cells under oxygen glucose deprivation

  2013cited by this paper
• Retracted: Equilibrative nucleoside transporter (ENT)‐1‐dependent elevation of extracellular adenosine protects the liver during ischemia and reperfusion

  2013cited by this paper
• P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model

  2013cited by this paper
• Mechanisms Limiting Distribution of the Threonine-Protein Kinase B-RaFV600E Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain Metastases

  2013cited by this paper
• Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver

  2013cited by this paper
• Altered UDP-Glucuronosyltransferase and Sulfotransferase Expression and Function during Progressive Stages of Human Nonalcoholic Fatty Liver Disease

  2013cited by this paper
• Hyperuricemia influences tryptophan metabolism via inhibition of multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP).

  2013cited by this paper
• Precise comparison of protein localization among OCT, OAT, and MATE in human kidney.

  2013cited by this paper
• Adenosine triphosphate‐binding cassette transporter genes up‐regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs

  2012cited by this paper
• Drug disposition in pathophysiological conditions.

  2012cited by this paper
• Regulatory Pathways for ATP-binding Cassette Transport Proteins in Kidney Proximal Tubules

  2012cited by this paper
• Expression of genes involved in xenobiotic metabolism and transport in end-stage liver disease: up-regulation of ABCC4 and CYP1B1

  2012cited by this paper
• ATP-binding cassette transporters in immortalised human brain microvascular endothelial cells in normal and hypoxic conditions

  2012cited by this paper
• Acute kidney injury

  2012cited by this paper
• Changes in expression of renal Oat1, Oat3 and Mrp2 in cisplatin-induced acute renal failure after treatment of JBP485 in rats.

  2012cited by this paper
• Membrane transporters in drug development.

  2012cited by this paper
• Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development.

  2012cited by this paper
• Altered Arsenic Disposition in Experimental Nonalcoholic Fatty Liver Disease

  2012cited by this paper
• Hepatocellular carcinoma

  2012cited by this paper
• Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS.

  2012cited by this paper
• Analysis of Global and Absorption, Distribution, Metabolism, and Elimination Gene Expression in the Progressive Stages of Human Nonalcoholic Fatty Liver Disease

  2011cited by this paper
• Acetaminophen Pharmacokinetics in Children With Nonalcoholic Fatty Liver Disease

  2011cited by this paper
• Variations in ATP-Binding Cassette Transporter Regulation during the Progression of Human Nonalcoholic Fatty Liver Disease

  2011cited by this paper
• The P-glycoprotein multidrug transporter.

  2011cited by this paper
• Increased expression of the multidrug resistance-associated protein 1 (MRP1) in kidney glomeruli of streptozotocin-induced diabetic rats

  2011cited by this paper
• The Role of Immune and Inflammatory Mechanisms in ALS

  2011cited by this paper
• Active efflux across the blood-brain barrier: Role of the solute carrier family

  2011cited by this paper
• P-glycoprotein expression and function are increased in an animal model of amyotrophic lateral sclerosis.

  2010cited by this paper
• Diversity in Antioxidant Response Enzymes in Progressive Stages of Human Nonalcoholic Fatty Liver Disease

  2010cited by this paper
• Mechanisms of multidrug resistance in cancer.

  2010cited by this paper
• Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy.

  2010cited by this paper
• Membrane transporters in drug development

  2010cited by this paper
• Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters.

  2010cited by this paper
• Novel Insights into the Pathophysiology of Nonalcoholic Fatty Liver Disease

  2010cited by this paper
• Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation

  2010cited by this paper
• XbaI GLUT1 Gene Polymorphism and the Risk of Type 2 Diabetes with Nephropathy

  2009cited by this paper
• Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats.

  2009cited by this paper
• ESRD impairs nonrenal clearance of fexofenadine but not midazolam.

  2009cited by this paper
• Reduced Antidiabetic Effect of Metformin and Down-regulation of Hepatic Oct1 in Rats with Ethynylestradiol-Induced Cholestasis

  2009cited by this paper
• New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)

  2009cited by this paper
• Acute kidney injury.

  2009cited by this paper
• Alteration of methotrexate biliary and renal elimination during extrahepatic and intrahepatic cholestasis in rats.

  2009cited by this paper
• Altered expression of MRP2, MRP3 and UGT2B1 in the liver affects the disposition of morphine and its glucuronide conjugate in a rat model of cholestasis

  2009cited by this paper
• Gender Differences in mRNA Expression of ATP-Binding Cassette Efflux and Bile Acid Transporters in Kidney, Liver, and Intestine of 5/6 Nephrectomized Rats

  2008cited by this paper
• Effect of 21-day exposure of phenobarbital, carbamazepine and phenytoin on P-glycoprotein expression and activity in the rat brain.

  2008cited by this paper
• Decreased Expression of Cytochromes P450 1A2, 2E1, and 3A4 and Drug Transporters Na+-Taurocholate-Cotransporting Polypeptide, Organic Cation Transporter 1, and Organic Anion-Transporting Peptide-C Correlates with the Progression of Liver Fibrosis in Chronic Hepatitis C Patients

  2008cited by this paper
• Diagnosis and treatment of hepatocellular carcinoma.

  2008cited by this paper
• Molecular targeted therapies in hepatocellular carcinoma

  2008cited by this paper
• Mechanisms of vascular calcification in chronic kidney disease.

  2008cited by this paper
• Ischemia-reperfusion of rat livers decreases liver and increases kidney multidrug resistance associated protein 2 (Mrp2).

  2008cited by this paper
• Altered Pharmacokinetics of Cationic Drugs Caused by Down-Regulation of Renal Rat Organic Cation Transporter 2 (Slc22a2) and Rat Multidrug and Toxin Extrusion 1 (Slc47a1) in Ischemia/Reperfusion-Induced Acute Kidney Injury

  2008cited by this paper
• Downregulation of organic anion transporters OAT1 and OAT3 correlates with impaired secretion of para-aminohippurate after ischemic acute renal failure in rats.

  2007cited by this paper
• Efflux Transporter Expression and Acetaminophen Metabolite Excretion Are Altered in Rodent Models of Nonalcoholic Fatty Liver Disease

  2007cited by this paper
• Hypoxia-induced changes in the expression of rat hepatobiliary transporter genes.

  2007cited by this paper
• Drug metabolite profiling and elucidation of drug-induced hepatotoxicity

  2007cited by this paper
• P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan

  2007cited by this paper
• Therapeutic drug monitoring of mycophenolic acid.

  2007cited by this paper
• Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites.

  2006cited by this paper
• Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1–3 and Multidrug and Toxin Extrusion Family)

  2006cited by this paper
• The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy.

  2006cited by this paper
• Expression and functional characteristics of tubular transporters: P-glycoprotein, PEPT1, and PEPT2 in renal mass reduction and diabetes.

  2006cited by this paper
• Differential regulation of transport proteins in the periinfarct region following reversible middle cerebral artery occlusion in rats.

  2006cited by this paper
• Differential regulation of transport proteins in the periinfarct region following reversible middle cerebral artery occlusion in rats

  2006cited by this paper
• Pharmacogenomics of human OATP transporters

  2006cited by this paper
• Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis.

  2005cited by this paper
• ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier.

  2005cited by this paper
• Blood-brain barrier active efflux transporters: ATP-binding cassette gene family

  2005cited by this paper

• Comparative Pharmacokinetics of Five Major Ingredients in Normal and Atherosclerotic Rats after Oral Administration of Shenlian Formula.

  2025cites this paper
• Comparative Tissue Distribution of 11 Components in Gerberae Piloselloidis Herba in Normal and Asthmatic Mice Using an Ultra‐High‐Performance Liquid Chromatography‐Electrospray Ionization‐Tandem Mass Spectrometry Method

  2025cites this paper
• Safety, pharmacokinetics, and efficacy of albuvirtide administered by intravenous bolus every 4 weeks in combination with oral dolutegravir in virologically suppressed adults living with HIV: A 24-week study.

  2025cites this paper
• Pharmacokinetic-pharmacodynamic and tissue distribution studies in physiological and cerebral ischemia-reperfusion injury rats after oral administration of anisodine hydrobromide tablets.

  2025cites this paper
• Comparisons of pharmacokinetics and tissue distribution of six major bioactive components of the herbal pair Alpinia officinarum-Cyperus rotundus in normal and primary dysmenorrhea rats.

  2024cites this paper
• Organic anion transporting polypeptides: Pharmacology, toxicology, structure, and transport mechanisms.

  2024cites this paper
• Pharmacokinetics of long-acting lenacapavir in participants with hepatic or renal impairment

  2024cites this paper
• INTERACTIONS OF BIOFLAVONOID ROBININ WITH EFFLUX TRANSPORTERS: P-GLYCOPROTEIN AND BREAST CANCER RESISTANCE PROTEIN

  2023cites this paper
• Gender Differences in a Mouse Model of Hepatocellular Carcinoma Revealed Using Multi-Modal Imaging

  2023cites this paper
• Assessing Liver Fibrosis Using 2D-SWE Liver Ultrasound Elastography and Dynamic Liver Scintigraphy with 99mTc-mebrofenin: A Comparative Prospective Single-Center Study

  2023cites this paper
• Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel

  2022cites this paper
• Quantitative Assessment of Liver Impairment in Chronic Viral Hepatitis with [99mTc]Tc-Mebrofenin: A Noninvasive Attempt to Stage Viral Hepatitis-Associated Liver Fibrosis

  2022cites this paper
• Comparative pharmacokinetics of eleven components from active part of Gerberae Piloselloidis Herba after oral administration in control and asthmatic mice.

  2022cites this paper
• Understanding the Blood‐Brain Barrier and Beyond: Challenges and Opportunities for Novel CNS Therapeutics

  2022cites this paper
• Metabolism and transporter based drug–drug interaction of tacrolimus with nine co-medicated injections

  2021cites this paper
• Global analysis of HBV-mediated host proteome and ubiquitylome change in HepG2.2.15 human hepatoblastoma cell line

  2021cites this paper
• Phytotherapeutics: The Rising Role of Drug Transporters in Herb-Drug Interactions with Botanical Supplements

  2021cites this paper
• Artichoke leaf extract supplementation lowers hepatic oxidative stress and inflammation and increases multidrug resistance-associated protein 2 in mice fed a high-fat and high-cholesterol diet.

  2021cites this paper
• Modeling alcohol-associated liver disease in a human Liver-Chip

  2021cites this paper
• Effects of 1α,25-Dihydroxyvitamin D3 on the Pharmacokinetics of Procainamide and Its Metabolite N-Acetylprocainamide, Organic Cation Transporter Substrates, in Rats with PBPK Modeling Approach

  2021cites this paper
• DOSE EXTRAPOLATION ACROSS POPULATIONS

  2021cites this paper
• Role of Physiologically Based Pharmacokinetic Modeling and Simulation in Enabling Model‐Informed Development of Drugs and Biotherapeutics

  2020cites this paper
• Extrahepatic Drug Transporters in Liver Failure: Focus on Kidney and Gastrointestinal Tract

  2020cites this paper
• Modeling alcoholic liver disease in a human Liver-Chip

  2020cites this paper
• Major glucuronide metabolites of testosterone are primarily transported by MRP2 and MRP3 in human liver, intestine and kidney.

  2019cites this paper
• Immunohistochemical Assessment of the Expression of Biliary Transportation Proteins MRP2 and MRP3 in Hepatocellular Carcinoma and in Cholangiocarcinoma

  2019cites this paper
• Identification and quantitation of enzyme and transporter contributions to hepatic clearance for the assessment of potential drug-drug interactions.

  2019cites this paper
• Protein Abundance of Clinically Relevant Drug Transporters in The Human Kidneys

  2019cites this paper
• CHARACTERIZATION OF RENAL SECRETION IN RENAL TRANSPLANT PATIENTS

  2018cites this paper
• Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention

  2018cites this paper
• Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients

  2018cites this paper
• Endogenous Probes for Drug Transporters: Balancing Vision With Reality

  2018cites this paper
• Pharmacokinetic changes of cefdinir and cefditoren and its molecular mechanisms in acute kidney injury in rats

  2018cites this paper
• Challenges with the precise prediction of ABC-transporter interactions for improved drug discovery

  2018cites this paper
• Epigenome-Wide Association (DNA Methylation) Study of Sex Differences in Normal Human Kidney

  2017cites this paper
• Role of Transporters in Drug Development

  2016cites this paper
• Recent advances in understanding hepatic drug transport

  2016cites this paper